Astrana Health (AMEH) Stock Forecast, Price Target & Predictions
AMEH Stock Forecast
Astrana Health stock forecast is as follows: an average price target of $48.50 (represents a 22.26% upside from AMEH’s last price of $39.67) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AMEH Price Target
AMEH Analyst Ratings
Astrana Health Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 19, 2022 | - | Lake Street | $40.00 | $29.45 | 35.82% | 0.83% |
Aug 08, 2022 | - | Barclays | $57.00 | $54.21 | 5.15% | 43.69% |
Astrana Health Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $39.67 | $39.67 | $39.67 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Dec 19, 2022 | Lake Street | - | Buy | Initialise |
Sep 21, 2022 | William Blair | - | Outperform | Initialise |
Aug 08, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
Astrana Health Financial Forecast
Astrana Health Revenue Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Jun 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | $335.62M | $292.85M | $261.70M | $174.39M | $163.90M | $94.69M | $122.23M |
Avg Forecast | $454.12M | $424.94M | $429.00M | $346.37M | $350.10M | $201.42M | $189.49M | $183.11M | $166.46M | $60.04M | $166.13M | $175.29M |
High Forecast | $454.12M | $424.94M | $466.10M | $352.30M | $350.10M | $241.70M | $227.38M | $219.73M | $199.75M | $72.05M | $199.35M | $210.34M |
Low Forecast | $454.12M | $424.94M | $391.90M | $335.00M | $350.10M | $161.13M | $151.59M | $146.48M | $133.17M | $48.03M | $132.90M | $140.23M |
# Analysts | 1 | 1 | 3 | 4 | 2 | 15 | 14 | 19 | 8 | 12 | 10 | 10 |
Surprise % | - | - | - | - | - | 1.67% | 1.55% | 1.43% | 1.05% | 2.73% | 0.57% | 0.70% |
Astrana Health EBITDA Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Jun 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 3 | 4 | 2 | 15 | 14 | 19 | 8 | 12 | 10 | 10 |
EBITDA | - | - | - | - | - | $33.36M | $20.77M | $32.68M | $26.95M | $12.46M | $770.19K | $14.42M |
Avg Forecast | $60.34M | $56.47M | $21.72M | $46.03M | $46.52M | $19.75M | $15.75M | $17.95M | $16.32M | $10.14M | $5.89M | $11.98M |
High Forecast | $60.34M | $56.47M | $26.07M | $46.81M | $46.52M | $23.70M | $18.90M | $21.54M | $19.58M | $12.17M | $7.07M | $14.38M |
Low Forecast | $60.34M | $56.47M | $17.38M | $44.51M | $46.52M | $15.80M | $12.60M | $14.36M | $13.06M | $8.12M | $4.72M | $9.59M |
Surprise % | - | - | - | - | - | 1.69% | 1.32% | 1.82% | 1.65% | 1.23% | 0.13% | 1.20% |
Astrana Health Net Income Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Jun 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 3 | 4 | 2 | 15 | 14 | 19 | 8 | 12 | 10 | 10 |
Net Income | - | - | - | - | - | $14.62M | $471.00K | $14.26M | $13.15M | $4.05M | $-2.45M | $7.87M |
Avg Forecast | $72.32M | $63.00M | $11.14M | $7.98M | $15.48M | $10.13M | $13.46M | $9.21M | $8.37M | $3.04M | $245.03K | $3.46M |
High Forecast | $72.32M | $63.00M | $13.37M | $9.38M | $15.48M | $12.15M | $16.16M | $11.05M | $10.04M | $3.65M | $294.04K | $4.16M |
Low Forecast | $72.32M | $63.00M | $8.91M | $7.04M | $15.48M | $8.10M | $10.77M | $7.36M | $6.70M | $2.43M | $196.03K | $2.77M |
Surprise % | - | - | - | - | - | 1.44% | 0.03% | 1.55% | 1.57% | 1.33% | -10.00% | 2.27% |
Astrana Health SG&A Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Jun 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 3 | 4 | 2 | 15 | 14 | 19 | 8 | 12 | 10 | 10 |
SG&A | - | - | - | - | - | $21.18M | $24.45M | $11.94M | $9.46M | $11.83M | $10.26M | $11.47M |
Avg Forecast | $31.57M | $29.54M | $8.02M | $24.08M | $24.34M | $7.29M | $16.23M | $6.62M | $6.02M | $8.88M | $18.01M | $14.91M |
High Forecast | $31.57M | $29.54M | $9.62M | $24.49M | $24.34M | $8.74M | $19.48M | $7.95M | $7.23M | $10.65M | $21.61M | $17.90M |
Low Forecast | $31.57M | $29.54M | $6.41M | $23.29M | $24.34M | $5.83M | $12.99M | $5.30M | $4.82M | $7.10M | $14.41M | $11.93M |
Surprise % | - | - | - | - | - | 2.91% | 1.51% | 1.80% | 1.57% | 1.33% | 0.57% | 0.77% |
Astrana Health EPS Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Jun 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 3 | 4 | 2 | 15 | 14 | 19 | 8 | 12 | 10 | 10 |
EPS | - | - | - | - | - | $0.31 | $0.01 | $0.32 | $0.31 | $0.08 | $-0.07 | $0.24 |
Avg Forecast | $1.54 | $1.34 | $0.35 | $0.17 | $0.33 | $1.43 | $1.95 | $1.43 | $0.14 | $0.03 | $0.14 | $0.13 |
High Forecast | $1.54 | $1.34 | $0.37 | $0.20 | $0.33 | $1.43 | $1.95 | $1.43 | $0.17 | $0.04 | $0.17 | $0.16 |
Low Forecast | $1.54 | $1.34 | $0.32 | $0.15 | $0.33 | $1.43 | $1.95 | $1.43 | $0.11 | $0.02 | $0.11 | $0.10 |
Surprise % | - | - | - | - | - | 0.22% | 0.01% | 0.22% | 2.21% | 2.76% | -0.51% | 1.85% |
Astrana Health Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ACHC | Acadia Healthcare Company | $42.33 | $82.33 | 94.50% | Buy |
HCSG | Healthcare Services Group | $11.17 | $17.33 | 55.15% | Hold |
SGRY | Surgery Partners | $29.22 | $44.33 | 51.71% | Buy |
AMED | Amedisys | $95.39 | $143.38 | 50.31% | Hold |
OPCH | Option Care Health | $22.49 | $32.75 | 45.62% | Buy |
EHAB | Enhabit | $7.63 | $10.25 | 34.34% | Hold |
AMEH | Astrana Health | $40.82 | $48.50 | 18.81% | Buy |
INNV | InnovAge | $5.90 | $6.80 | 15.25% | Hold |
SEM | Select Medical | $36.51 | $40.00 | 9.56% | Buy |
PNTG | Pennant Group | $32.38 | $34.67 | 7.07% | Buy |
ADUS | Addus HomeCare | $128.96 | $129.40 | 0.34% | Buy |
UHS | Universal Health Services | $208.83 | $208.47 | -0.17% | Hold |
EHC | Encompass Health | $100.23 | $97.00 | -3.22% | Buy |
ENSG | Ensign Group | $153.39 | $148.20 | -3.38% | Buy |
AMEH Forecast FAQ
Is Astrana Health a good buy?
Yes, according to 3 Wall Street analysts, Astrana Health (AMEH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of AMEH's total ratings.
What is AMEH's price target?
Astrana Health (AMEH) average price target is $48.5 with a range of $40 to $57, implying a 22.26% from its last price of $39.67. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Astrana Health stock go up soon?
According to Wall Street analysts' prediction for AMEH stock, the company can go up by 22.26% (from the last price of $39.67 to the average price target of $48.5), up by 43.69% based on the highest stock price target, and up by 0.83% based on the lowest stock price target.
Can Astrana Health stock reach $60?
AMEH's average twelve months analyst stock price target of $48.5 does not support the claim that Astrana Health can reach $60 in the near future.
What are Astrana Health's analysts' financial forecasts?
AMEH's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $897.89M (high $944.1M, low $846.23M), average EBITDA is $112.3M (high $117.03M, low $106.83M), average net income is $33.59M (high $37.02M, low $30.62M), average SG&A $55.7M (high $57.57M, low $53.46M), and average EPS is $1.93 (high $1.96, low $1.91).
Did the AMEH's actual financial results beat the analysts' financial forecasts?
Based on Astrana Health's last annual report (Dec 2022), the company's revenue was $1.14B, beating the average analysts forecast of $372.59M by 205.43%. Apple's EBITDA was $133.35M, beating the average prediction of $33.71M by 295.62%. The company's net income was $49.05M, beating the average estimation of $22.67M by 116.36%. Apple's SG&A was $77.67M, beating the average forecast of $22.86M by 239.81%. Lastly, the company's EPS was $1.09, missing the average prediction of $3.38 by -67.78%. In terms of the last quarterly report (Mar 2023), Astrana Health's revenue was $335.62M, beating the average analysts' forecast of $201.42M by 66.63%. The company's EBITDA was $33.36M, beating the average prediction of $19.75M by 68.94%. Astrana Health's net income was $14.62M, beating the average estimation of $10.13M by 44.40%. The company's SG&A was $21.18M, beating the average forecast of $7.29M by 190.67%. Lastly, the company's EPS was $0.31, missing the average prediction of $1.43 by -78.31%